CXCR4-modification boosts CAR-T cell efficacy by improving tumor tracking and bone marrow homing in B cell malignancies [In vitro]
RNA-seq (gene expression) · human · 20 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 20 samples: 7 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- CXCR4-modification enhances CAR-T efficacy by improving tumor tracking and bone marrow homing in B-cell malignanciesSignal transduction and targeted therapy · 2026
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE305732_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1305189 and SRA study SRP608613. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 18 samples.
How we read this: 7 replicated groups read from 20 sample titles; they account for 18 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9183644 CD19_C_CART_1
- GSM9183645 NT_1 NT
- GSM9183646 NT_2 NT
- GSM9183647 NT_R_1 NT
- GSM9183648 NT_R_2 NT
- GSM9183650 NT_RS_1 NT_RS
- GSM9183651 NT_RS_2 NT_RS
- GSM9183652 NT_S_1 NT_S
- GSM9183653 NT_S_2 NT_S
- GSM9183655 CD19_CART_1 CD19_CART
- GSM9183656 CD19_CART_2 CD19_CART
- GSM9183657 CD19_CART_R_1 CD19_CART
- GSM9183658 CD19_CART_R_2 CD19_CART
- GSM9183660 CD19_CART_RS_1 CD19_CART_RS
- GSM9183661 CD19_CART_RS_2 CD19_CART_RS
- GSM9183662 CD19_CART_S_1 CD19_CART_S
- GSM9183663 CD19_CART_S_2 CD19_CART_S
- GSM9183665 CD19_C_CART_RS_2
- GSM9183666 CD19_C_CART_S_1 CD19_C_CART_S
- GSM9183667 CD19_C_CART_S_2 CD19_C_CART_S
- GSE314992 Expression of the CXCR4 S338X variant improves anti-leukemia efficacy of anti-CD19 CAR-T cells 20 samples shares car-t, efficacy
- GSE291458 Supplementing CD2 expression enhances CAR-T Cell Efficacy through Optimizing CAR-immunological Synapse formation 18 samples shares car-t, efficacy
- GSE320375 On-demand GLUT3 expression augments CAR-T cell metabolic fitness and antitumor efficacy whereas preventing toxicity in glioblastoma 16 samples shares car-t, efficacy
- GSE231429 Placental T cells retain enhanced stemness and altered cytokine response favoring durable efficacy of CD19 CAR-T 13 samples shares car-t, efficacy
- GSE277818 Targeting PRC2 enhances the antitumor cytotoxic capacity of anti-CD19 CAR-T cells against hematological malignancies 12 samples shares car-t, malignancies
- GSE328224 Reprogramming CAR with cytokine signaling increases the efficacy of CAR-T cell therapy in solid tumour treatment and confers sustained immune memory 11 samples shares car-t, efficacy
- GSE315646 Humanized and Charge-Optimized CSPG4-Specific CAR-T Cells Show Enhanced Efficacy Against Head and Neck Squamous Cell Carcinoma 10 samples shares car-t, efficacy
- GSE328225 Reprogramming CAR with cytokine signaling increases the efficacy of CAR-T cell therapy in solid tumour treatment and confers sustained immune memory [Tumor infiltrated CAR-T cells] 10 samples shares car-t, efficacy
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.